Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
366 studies found for:    Open Studies | "Myelodysplastic Syndromes"
Show Display Options
Rank Status Study
21 Recruiting An Open-Label Study of Recormon (Epoetin Beta) Treatment in Anemic Patients With Myelodysplastic Syndrome
Condition: Myelodysplastic Syndromes
Intervention: Drug: epoetin beta [Recormon]
22 Recruiting Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Interventions: Drug: Volasertib;   Drug: Azacitidine
23 Recruiting A Safety and Pharmacology Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Interventions: Drug: Atezolizumab [TECENTRIQ];   Drug: Azacitidine
24 Recruiting Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q
Condition: Myelodysplastic Syndromes
Interventions: Drug: Eltrombopag/Revolade;   Other: Placebo;   Drug: Lenalidomide
25 Recruiting A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy.
Condition: Myelodysplastic Syndrome
Interventions: Procedure: Bone marrow aspirate;   Drug: Deferasirox
26 Recruiting The National Myelodysplastic Syndromes (MDS) Study
Condition: Myelodysplastic Syndromes (MDS)
Intervention: Other: Therapeutic
27 Not yet recruiting A Study Evaluating Venetoclax in Combination With Azacitidine Compared With Azacitidine Alone in Participants With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Condition: Myelodysplastic Syndromes (MDS)
Interventions: Drug: venetoclax;   Drug: azacitidine
28 Recruiting A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Interventions: Drug: Luspatercept;   Other: Placebo
29 Recruiting A Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS)
Condition: Myelodysplastic Syndromes (MDS)
Intervention: Drug: decitabine
30 Recruiting CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy
Condition: Previously Treated Myelodysplastic Syndromes
Intervention: Drug: 6,8-bis(benzylthio)octanoic acid
31 Recruiting A Prospective, Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes (MDS)
Intervention: Other: No interventions
32 Not yet recruiting Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure
Condition: Previously Treated Myelodysplastic Syndrome
Interventions: Drug: Entinostat;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
33 Recruiting Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.
Conditions: Adult Patients With Low Risk Myelodysplastic Syndrome;   Adult Patients With Int 1-risk Myelodysplastic Syndrome
Interventions: Drug: Erythropoietin alpha;   Drug: Deferasirox
34 Not yet recruiting A Study Evaluating Venetoclax in Combination With Azacitidine Compared With Azacitidine Alone in Participants With Previously Untreated Higher-Risk Myelodysplastic Syndromes (MDS)
Condition: Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
Interventions: Drug: Venetoclax;   Drug: Azacitidine
35 Recruiting The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)
Condition: Myelodysplastic Syndrome
Interventions: Drug: Oral Azacitidine;   Drug: Placebo
36 Recruiting Quality of Life and Symptoms in Patients With Newly Diagnosed Myelodysplastic Syndromes
Conditions: Adult;   Myelodysplastic Syndromes
Interventions: Other: questionnaire administration;   Other: fatigue assessment and management;   Other: observation;   Other: quality-of-life assessment
37 Recruiting Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS)
Conditions: Leukemia;   Myelodysplastic Syndrome
Interventions: Drug: Nivolumab;   Drug: Ipilimumab;   Drug: 5-azacitidine
38 Recruiting A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)
Conditions: Myelodysplastic Syndromes;   Thrombocytopenia
Intervention: Drug: Eltrombopag
39 Recruiting CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT.
Conditions: Myelodysplastic Syndromes;   Acute Leukemia
Intervention: Drug: CIK-Cells
40 Recruiting A Dose Escalation and Cohort Expansion Study of RO6870810/TEN-010 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Condition: Myelodysplastic Syndromes, Acute Myeloid Leukemia
Intervention: Drug: TEN-010

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.